This is an old revision of the document!
Anakinra
Anakinra is a recombinant human interleukin-1 receptor antagonist (IL-1Ra). It competitively inhibits binding of IL-1α and IL-1β to the IL-1 receptor type 1. Given daily as subcutaneous injection, it has modest but significant anti-inflammatory efficacy in Rheumatoid arthritis and has been proven of particular benefit in autoinflammatory syndromes, where IL-1 seems to play a pivotal role.
Anakinra has been reported to be useful in refractory seizures in the chronic phase of FIRES[1].
Discussion